Mr. Pratap Sandhu reports

THE PRECISION PEPTIDE COMPANY INC. PLACES ORDER FOR 20,000 BPC-157 TRANSDERMAL PATCHES

The Precision Peptide Company Inc. has placed an order for 20,000 units of its BPC-157 transdermal patch, the company's lead product candidate. The order is intended to support the patch's planned commercial release. Each patch is formulated to deliver two milligrams of BPC-157. An initial commercial release of the BPC-157 transdermal patch could begin as early as June, 2026, through The Precision Peptide Company website.

The order follows The Precision Peptide Company's news release dated May 19, 2026 (previously announced), in which the company reported independent third party test results for the patch. As disclosed in that release, the patch was tested by Miraxis Labs (San Diego, Calif.), an independent U.S. analytical laboratory, using ultrahigh performance liquid chromatography with diode array detection, and the results were certified by Dr. David Marelius, PhD (chief scientific officer of Miraxis Labs), and Dr. Erik Paulson, PhD (lab director).

Those results confirmed 95.5-per-cent chromatographic purity, exceeding the greater-than-or-equal-to-95-per-cent threshold widely recognized across the peptide industry as the analytical benchmark for high-purity grade peptide products1, and a quantified dose of 2.02 milligrams of BPC-157 per patch. The two-milligram formulated dose under this order is consistent with the previously reported quantified potency.

Pratap Sandhu, chief executive officer of The Precision Peptide Company, commented: "We have placed an order for 20,000 transdermal patches. Following our third party test results, this order marks an important step in advancing the patch from a validated formulation toward commercial production. We look forward to sharing further developments as we prepare for the commercial release of our lead product."

About The Precision Peptide Company Inc.

Precision Peptide Company is a publicly traded wellness company building a next-generation platform for high-quality peptide formulations. By combining scientific formulation and innovative delivery technologies, the company creates products at the intersection of biotechnology and scalable consumer wellness. Products are manufactured in an approved U.S. facility and distributed across North America.

We seek Safe Harbor.